Literature DB >> 19490402

Pseudo-guillain-barre syndrome due to "whippet"-induced myeloneuropathy.

William O Tatum1, Daniel D Bui, Edmund G Grant, Ryan Murtagh.   

Abstract

Guillain-Barre syndrome (GBS) is the rubric encompassing highly variable phenotypic subgroups of acute, postinfectious, immune-mediated peripheral neuropathy. The hallmark of GBS phenomenology is a rapidly progressive ascending lower extremity weakness. GBS taxonomy includes a motor and sensory axonal neuropathy (AMSAN). Nitrous oxide (NO) abuse may create a pattern of neurological dysfunction almost identical to subacute combined degeneration. We report an adult with myeloneuropathy due to NO abuse that mimicked the presenting features of the GBS-subtype AMSAN.
Copyright © 2009 by the American Society of Neuroimaging.

Entities:  

Mesh:

Year:  2010        PMID: 19490402     DOI: 10.1111/j.1552-6569.2009.00388.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  5 in total

1.  Subacute combined degeneration of the spinal cord following recreational nitrous oxide use.

Authors:  Hui Mei Cheng; Jae Hong Park; David Hernstadt
Journal:  BMJ Case Rep       Date:  2013-03-08

2.  Assessment of reinforcement enhancing effects of toluene vapor and nitrous oxide in intracranial self-stimulation.

Authors:  Matthew E Tracy; Galina G Slavova-Hernandez; Keith L Shelton
Journal:  Psychopharmacology (Berl)       Date:  2013-11-02       Impact factor: 4.530

3.  Recurrent paraparesis and death of a patient with 'whippet' abuse.

Authors:  Jouni Hirvioja; Juho Joutsa; Pia Wahlsten; Jaana Korpela
Journal:  Oxf Med Case Reports       Date:  2016-03-16

Review 4.  Peripheral polyneuropathy and acute psychosis from chronic nitrous oxide poisoning: A case report with literature review.

Authors:  Radhika Sood; Thibault Parent
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

Review 5.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.